🇺🇸 Dexamethasone + Ondansetron in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 8

Most-reported reactions

1. Chills — 1 report (12.5%)
2. Dyspnoea — 1 report (12.5%)
3. General Symptom — 1 report (12.5%)
4. Hypersensitivity — 1 report (12.5%)
5. Hypertension — 1 report (12.5%)
6. Hypoxia — 1 report (12.5%)
7. Pancreatitis — 1 report (12.5%)
8. Tachypnoea — 1 report (12.5%)

Source database →

Frequently asked questions

Is Dexamethasone + Ondansetron approved in United States?

Dexamethasone + Ondansetron does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Dexamethasone + Ondansetron in United States?

University of Catania is the originator. The local marketing authorisation holder may differ — check the official source linked above.